Comparative Pharmacology
Head-to-head clinical analysis: PHOSPHOTOPE versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSPHOTOPE versus QUADRAMET.
PHOSPHOTOPE vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients.
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical